助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   autologous transplant 在 肿瘤学 分类中 的翻译结果: 查询用时:0.495秒
图标索引 在分类学科中查询
所有学科
肿瘤学
儿科学
更多类别查询

图标索引 历史查询
 

autologous transplant
相关语句
  “autologous transplant”译为未确定词的双语例句
    Methods Retrospective analysis for autologous transplant mainly with intravenous melphalan in 43 children with advanced malignant solid tumours was performed in our center.
    方法用回顾性分析的方法,对43例以静脉马法兰为主的预处理移植治疗的儿童高危恶性肿瘤临床资料进行分析。
短句来源
    Totally 45 autologous transplant were finished among these 43 patients because 2 patients received 2 consecutive transplants including 8 with bone marrow transplant and 37 with peripheral precursor transplant. The dosage of melphaelan was 140 mg/m2 in 8 cases, 180 mg/m2 in 10 cases and 210 mg/m2 in rest of 27 cases.
    因2例患儿连续进行2次移植,43例患儿共进行45例次移植,8例为骨髓移植、37例次为外周血造血干细胞移植,8例次患儿应用140mg/m2马法兰,10例应用180mg/m2马法兰,其余27例次应用210mg/m2马法兰。
短句来源
    Report on the autologous transplant mainly conditioned with intravenous melphalan in 43 chinese children with advanced malignant solid tumours
    以静脉马法兰为主的预处理自身移植治疗43例儿童高危恶性实体肿瘤
短句来源
    High-dose chemotherapy accompanied by hematopoietic stem-cell support via autologous transplant is recommended up to the age of 65 -70 years.
    在65~70岁年龄组患者中推荐大剂量化疗联合经自体造血干细胞移植的治疗方案。
短句来源
查询“autologous transplant”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  autologous transplant
Although autologous transplantation has improved outcomes for younger patients, the use of a second autologous transplant in the relapsed setting has less benefit.
      
Therapeutic options for patients with hodgkin's disease and non-hodgkin's lymphoma who relapse after autologous transplant
      
Allogeneic transplant patients reported higher pain intensity than did autologous transplant patients.
      
One case was positive at the beginning of CR and became negative after autologous transplant.
      
Peripheral blood stem cell CD34+ autologous transplant in relapsed follicular lymphoma
      
更多          


Objective CD34 + is an immunophenotype of hematopoietic stem cells/progenitors. CD34 + cells selection in vitro may deplete T cells 4 5 logs and tumor cells 3 4 logs. It will benefit to mismatched related donor allo transplantation and autologous transplantation of tumor diseases. Methods 19 patients aged 29 (5~52) years were treated by allo ( n =5) or auto PB CD34 + cells transplantation ( n =14). Grafts from fifteen patients with various disorders (3 lymphomas, 6 multiple myelomas, 2 SLE,...

Objective CD34 + is an immunophenotype of hematopoietic stem cells/progenitors. CD34 + cells selection in vitro may deplete T cells 4 5 logs and tumor cells 3 4 logs. It will benefit to mismatched related donor allo transplantation and autologous transplantation of tumor diseases. Methods 19 patients aged 29 (5~52) years were treated by allo ( n =5) or auto PB CD34 + cells transplantation ( n =14). Grafts from fifteen patients with various disorders (3 lymphomas, 6 multiple myelomas, 2 SLE, 1 Sjogren's syndrome, 2 breast cancer and 1 medulloblastoma) and five haploidentical donors for leukemia patients (1 ALL CR2, 2 AML rel, 1 CML CP and 1 MDS RAEB) were isolated using magnetic activated cell sorting (CliniMACS, Milteny Biotech, Germany). Results After separation, purity of CD34 + cells was >97 %. Depletion of CD34 negative cells was extensive: CD3 + 2.6~4.6 logs, CD4 + >5 logs, CD8 + 4.6 > 5 logs, and CD19 + 1.2~3.1 logs. 19 patients who received selected CD34 + cells transplantation (CD34 +CT) were followed up for 11(1~20) months. Overall survival(OS) was 13/19 (68.4%) cases. 1/5 patients with haploidentical transplant had disease free survival for 19 months. 12/14(85.7%) auto CD34 +CT achieved overall survival(OS). Conclusion Selected CD34 + cells transplantation significantly decreases the incidence of >Ⅱ GVHD and depletes tumor cell contamination. This approach may be useful to haploidentical or unrelated donor transplantation. It also benefits autologous transplant in various tumor disorders.

目的 观察富集CD34+的造血干 /祖细胞做肿瘤患者同种异基因造血干细胞移植 (Allo HSCT)和自体移植的临床疗效。观察输注纯化CD34+细胞患者的预后情况。方法 采用磁分选临床型细胞富集仪将表面包被有CD34单抗的磁性微球体系与细胞共同培养 ,特异性结合CD34+细胞。在磁场作用下分别收集CD34+和CD34-组分。完成 2 0例患者CD34+细胞体外纯化富集。其中HLA半相合移植 5例 ,自体移植 15例。结果 纯化后CD34+细胞纯度达 97%以上 ,移植CD34+细胞中位数 5 .72 (0 .15~ 12 .0 )× 10 6,CD34+细胞中位数 3.73(2 .6~ 6 .8)× 10 4 ;CD34-细胞 (CD3、CD4、CD8、CD19)对数去除率 (Log,下同 )为 1.99~ 5 .0。 19例患者移植后随访 11个月 (中位数 ,1~ 2 0 ) ,总体生存13/ 19(例 )。本院 11例中 ,总体生存为 8/ 11(例 ) ,其中HLA半相合 1/ 3(例 ) ,自体移植 7/ 8(例 )。移植后造血重建迅速 ,随访 18个月以上无病生存者 3例中 1例为同种异基因HLA...

目的 观察富集CD34+的造血干 /祖细胞做肿瘤患者同种异基因造血干细胞移植 (Allo HSCT)和自体移植的临床疗效。观察输注纯化CD34+细胞患者的预后情况。方法 采用磁分选临床型细胞富集仪将表面包被有CD34单抗的磁性微球体系与细胞共同培养 ,特异性结合CD34+细胞。在磁场作用下分别收集CD34+和CD34-组分。完成 2 0例患者CD34+细胞体外纯化富集。其中HLA半相合移植 5例 ,自体移植 15例。结果 纯化后CD34+细胞纯度达 97%以上 ,移植CD34+细胞中位数 5 .72 (0 .15~ 12 .0 )× 10 6,CD34+细胞中位数 3.73(2 .6~ 6 .8)× 10 4 ;CD34-细胞 (CD3、CD4、CD8、CD19)对数去除率 (Log,下同 )为 1.99~ 5 .0。 19例患者移植后随访 11个月 (中位数 ,1~ 2 0 ) ,总体生存13/ 19(例 )。本院 11例中 ,总体生存为 8/ 11(例 ) ,其中HLA半相合 1/ 3(例 ) ,自体移植 7/ 8(例 )。移植后造血重建迅速 ,随访 18个月以上无病生存者 3例中 1例为同种异基因HLA半相合亲属移植 ,2例为肿瘤自体移植。 1例父子间HLA半相合移植 ,白细胞恢复 >1× 10 9/L ,血小板 >2 0× 10 9/L(均为移植后第 13天 )。仅有短暂的I度移植物抗宿主疾病。 2例自体移植病例白细胞恢复 >1× 10 9/L(8~ 2 6d) ,血小板恢复 >2 0× 10 9/L(2 2~ 35d)。结论 

Summary Multiple Myeloma ( MM) is characterised by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunoglobulin. The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40% -60% and in a median survival time of approximately 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Most randomized trials have frailed to show a significant improvement in survival time when...

Summary Multiple Myeloma ( MM) is characterised by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunoglobulin. The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40% -60% and in a median survival time of approximately 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Most randomized trials have frailed to show a significant improvement in survival time when combination chemotherapy is used instead of melphalan with or without prednisone. The benefit of maintenance therapy with interferon-alpha has been demonstrated. The toxicity of interferon-alpha, which may reduce the quality of life, should be considered. Recently, myeloma-treatment has been modified. High-dose chemotherapy accompanied by hematopoietic stem-cell support via autologous transplant is recommended up to the age of 65 -70 years. First results from a French study comparing single versus double autologous transplantation have shown a benefit in terms of event-free survival for the sequential approach. Vaccinations as an adoptive immuntherapy to treat minimal residual disease are under way. The mortality rale of allogeneic transplantation of hematopoietic stem cells has been reduced in the last 5 years. The use of reduced conditioning regimens or the partial depletion of T cells in peripheral blood stem cell transplants in an effort to decrease transplant related mortality are promising approaches. Thalid-omide and its derivates are a new class of agents with independent anti-tumour activity in MM. Encouraging results with this antian-giogenic therapy in phase II trials have been reported. Supportive therapies, such as the treatment of anaemia with erythropoietin, the management of renal failure and the use of bisphosphonates, improve the life quality of MM patients.

目的 多发性骨髓瘤是以骨髓内恶性浆细胞聚集而产生单克隆免疫球蛋白为特点的一种疾病。一般保守疗法是采用左旋苯丙氨酸联合强的松用药,有效率可达40%~60%,平均存活时间大约为3年。为进一步提高疗效,临床上曾尝试多种治疗方案,发现使用联合化疗方案与单用左旋苯丙氨酸及左旋苯丙氨酸加强的松相比,能有效地延长患者的生存时间。α-干扰素有较好的支持治疗作用,但α-干扰素的毒副作用对降低患者的生活质量,应引起重视。 近来骨髓瘤治疗方法有改进。在65~70岁年龄组患者中推荐大剂量化疗联合经自体造血干细胞移植的治疗方案。最先的一项来自法国的研究结果表明,比较单自体移植对双自体移植,对在后继的无病生存方面的研究有帮助。作为过继免疫疗法的免疫接种是为了治疗小的残余病灶,目前正在进行中。在过去的5年里,同种异体干细胞移植的死亡率已明显下降。采用减少预治疗或外周干细胞移植中T细胞的部分剔除可降低与移植相关的死亡率,是一种有前途的研究方法。酞胺哌啶酮及其衍物作为一类新的药物,在多发性骨髓瘤的治疗中具有独到的抗肿瘤活性作用。抗血管生成治疗已有Ⅱ期实验报道,这一结果令人鼓舞。通过使用促红细胞生成素治疗贫血、肾功能衰竭的防治及磷酸二酯的应用等...

目的 多发性骨髓瘤是以骨髓内恶性浆细胞聚集而产生单克隆免疫球蛋白为特点的一种疾病。一般保守疗法是采用左旋苯丙氨酸联合强的松用药,有效率可达40%~60%,平均存活时间大约为3年。为进一步提高疗效,临床上曾尝试多种治疗方案,发现使用联合化疗方案与单用左旋苯丙氨酸及左旋苯丙氨酸加强的松相比,能有效地延长患者的生存时间。α-干扰素有较好的支持治疗作用,但α-干扰素的毒副作用对降低患者的生活质量,应引起重视。 近来骨髓瘤治疗方法有改进。在65~70岁年龄组患者中推荐大剂量化疗联合经自体造血干细胞移植的治疗方案。最先的一项来自法国的研究结果表明,比较单自体移植对双自体移植,对在后继的无病生存方面的研究有帮助。作为过继免疫疗法的免疫接种是为了治疗小的残余病灶,目前正在进行中。在过去的5年里,同种异体干细胞移植的死亡率已明显下降。采用减少预治疗或外周干细胞移植中T细胞的部分剔除可降低与移植相关的死亡率,是一种有前途的研究方法。酞胺哌啶酮及其衍物作为一类新的药物,在多发性骨髓瘤的治疗中具有独到的抗肿瘤活性作用。抗血管生成治疗已有Ⅱ期实验报道,这一结果令人鼓舞。通过使用促红细胞生成素治疗贫血、肾功能衰竭的防治及磷酸二酯的应用等支持疗法,可以进一步提高多发?

5-Aminolevulinic acid-based photodynamie therapy (ALA-PDT) is a relatively new modality to cancer treatment.Be- cause of a preferable uptake of endogenous photosensitizer(PpIX) derived from ALA in neoplastic cells,there is a selective destruction of tumor.The studies on leukemia are limited in basic research today.We will review the mechanism of the cytotoxic effects on leukemic cell lines,studies on multidrug resistance,bone marrow purging in autologous transplants and application prospect of ALA-PDT.

ALA-PDT是一种较新型的肿瘤治疗手段。由于肿瘤细胞对ALA产生的内源性光敏剂原卟啉IX(PpIX)的优先摄取,使肿瘤细胞被选择性地杀伤。目前在白血病领域,ALA-PDT仍限于基础研究。本文将就ALA-PDT在白血病细胞株中的作用机制、白血病耐药、自体移植体外净化中的应用及前景进行综述。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关autologous transplant的内容
在知识搜索中查有关autologous transplant的内容
在数字搜索中查有关autologous transplant的内容
在概念知识元中查有关autologous transplant的内容
在学术趋势中查有关autologous transplant的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社